Accelerated Access Review: interim report published
Consensus framework for HEEs of vaccines in Europe
Developing countries push for drug patent extension
Generics save NHS £, but not a quick fix
Healthcare insurance coverage low in US
Irish cost-effectiveness threshold too high?
NICE's approval of hepatitis drugs may create cost dilemma
Remicade price reduction in UK
UK drug-pricing campaigners deliver petition to Roche
Antiviral prophylaxis cost saving for preventing perinatal HBV
Apixaban cost effective for prevention of stroke
Are additional costs of HIV screening algorithms justified?
BOTOX cost effective for overactive bladder
Cancer has economic impact on US patients
Cardiovascular drugs unaffordable in many communities
Choosing Wisely: modest changes from early recommendations
Dementia increases end-of-life expenditure
Direct cost of CRS in the US higher than previously estimated
FFRCT may reduce costs in evaluation of suspected CAD
HCV screening in US military saves costs
Home IV antibiotic infusion program cost saving
Hospital antibiotic stewardship programme cost saving
Kidney donor compensation - a small cost for large welfare gain
Linked real-world datasets enable IBS cost analysis
PBSS can quantify misuse of prescribed controlled substances
Physician-hospital integration increases outpatient spending
Screening and treatment of SCA cost effective in neonates
Stepping down asthma medication reduces costs
Video interpretation improves communication with patients
Viral load testing cost saving in patients on first-line ART
NICE approves idelalisib and tolvaptan, not Abraxane
NICE draft guidance recommends four drugs for JIA
NICE recommends ezetimibe for hypercholsterolaemia
NICE: more info needed for new pre-eclampsia tests
Plans for more patient-focused NHS culture in UK
Ponatinib listed for CML and ALL in Australia
Riociguat (Adempas) recommended in Wales